Altimmune to Participate at Leerink Partners Therapeutics Forum
2024年7月2日 - 8:30PM
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical
company, today announced that members of the Company’s management
team will be hosting one-on-one meetings with institutional
investors at the Leerink Partners Therapeutics Forum: I&I and
Metabolism, being held on July 9 and 10, 2024 in Boston, MA. The
event will feature analyst-hosted panel discussions with leading
physicians in a range of autoimmune and metabolic indications, as
well as meetings between participating companies and investors.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical
company focused on developing innovative next-generation
peptide-based therapeutics. The Company is developing pemvidutide,
a GLP-1/glucagon dual receptor agonist for the treatment of obesity
and MASH. For more information, please
visit www.altimmune.com.
Follow @Altimmune, Inc.
on LinkedInFollow
@AltimmuneInc on Twitter
Company Contact:Vipin GargPresident and Chief
Executive OfficerPhone: 240-654-1450ir@altimmune.com
Investor Contacts:Lee RothBurns McClellanPhone:
646-382-3403lroth@burnsmc.com
Julia WeilmanBurns McClellanPhone:
646-732-4443jweilman@burnsmc.com
Media Contact:Danielle CanteyInizio Evoke,
BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 6 2024 まで 7 2024
Altimmune (NASDAQ:ALT)
過去 株価チャート
から 7 2023 まで 7 2024
